En fase 2-studie av PCS6422 med capecitabin hos pasienter med avansert eller metastatisk brystkreft
En fase 2, åpen studie av PCS6422 med capecitabin hos pasienter med avansert eller metastatisk brystkreft
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with Cap vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who have been treated with chemotherapy in the metastatic setting.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90067
- Valkyrie Clinical Trials
-
Oxnard, California, Forente stater, 93030
- FOMAT Medical Research
-
-
Florida
-
Miami, Florida, Forente stater, 33165
- AP Medical Research
-
Tampa, Florida, Forente stater, 33612
- Moffitt Cancer Center
-
-
Indiana
-
Dyer, Indiana, Forente stater, 46311
- Northwest Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland Medical Center (UMMC)
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Westbury, New York, Forente stater, 11590
- Clinical Research Alliance
-
-
Ohio
-
Canton, Ohio, Forente stater, 44718
- Gabrail Cancer Center Research
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Forente stater, 78731
- Texas Oncology PA (Austin)
-
San Antonio, Texas, Forente stater, 78240
- Texas Oncology PA (San Antonio)
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Aged ≥18 years at Screening
-
Diagnosis of histologically confirmed breast cancer that is unresectable. The following subsets of breast cancer are included:
- Patients with triple-negative breast cancer, advanced or metastatic
- Patients with hormone receptor (HR) positive, ER positive, HER2 negative advanced or metastatic breast cancer
-
Has measurable disease in accordance with RECIST 1.1 obtained by imaging within 28 days prior to C1D1
-
Other therapies are not indicated (eg, resistant or intolerant to taxanes and/or an anthracycline-containing regimen) for treatment of advanced or metastatic breast cancer
-
Has a life expectance of at least 24 weeks
-
Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at screening
-
Has adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days before C1D1 (Note: labs will also be repeated pre-dose on C1D1 to confirm eligibility): a. Hemoglobin ≥9 g/dL (≥90 g/L) b. Adequate renal function by estimated glomerular filtration rate (eGFR) defined as a creatinine clearance >50 mL/min (>0.84 mL/s) (Cockcroft-Gault equation) and normalized to body surface area c. Peripheral absolute neutrophil count (ANC) of ≥1.5×109/L d. Platelet count of ≥100×109/L without growth factor/transfusion e. Total bilirubin <1.5× upper limit of normal (ULN); or ≤3×ULN if the patient has Gilbert's disease f. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <2.5×ULN, with liver metastasis <5×ULN g. International normalized ratio (INR) <1.5 and prothrombin time (PT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulant h. Activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless both of the following conditions are met: i. Patient is receiving anticoagulant therapy, and ii. PT or PTT is within therapeutic range of intended use of anticoagulants
Exclusion Criteria:
-
Received any line of treatment for advanced or metastatic breast cancer within 21 days or 5 half-lives (whichever is longer) prior to randomization
-
Currently receiving any hormone replacement therapy, unless discontinued within 21 days prior to randomization
-
Received IV 5-FU or oral 5-FU analog in the 4 weeks prior to C1D1
-
Received DPD inhibitor within 4 weeks prior to C1D1
-
Has homozygous or compound heterozygous DPYD variants that result in complete or near-complete absence of DPD activity
-
Cardiac:
-
Has history or presence of clinically significant abnormal 12-lead electrocardiogram (ECG) results, in the Medical Monitor or Investigator's opinion
-
Has prolonged QTc (with Fridericia's correction) of >480 msec performed at Screening
-
Has a history of prolonged QTc interval, ventricular tachycardia/fibrillation or significant ventricular arrhythmia, or Torsades de Pointes, or a history of ventricular ablation for arrhythmia
-
Has congenital long QT syndrome or a family history of long QT syndrome
-
Has other clinically significant cardiac disease including, but not limited to, myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery ≤12 months prior to randomization, congestive heart failure
- Class II per the New York Heart Association, or history of myocarditis
-
-
Is pregnant or breastfeeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: PCS6422 40 mg + Capecitabine 300 mg
Fixed single dose of PCS6422 administered with Capecitabine 150 mg BID over 7 days |
PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Andre navn:
|
|
Eksperimentell: PCS6422 40 mg + Capecitabine 450 mg or 150 mg
Fixed single dose of PCS6422 administered with Capecitabine 225 mg or 75 mg BID over 7 days |
PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer.
Andre navn:
|
|
Aktiv komparator: Capecitabine 2000 mg/m2
Standard capecitabine dose at 1000 mg/m2 BID |
Commercially available capecitabine is a commonly used oral fluoropyrimidine.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluation of Objective Response Rate (ORR)
Tidsramme: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients who achieved a confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) |
Up to 24 weeks post End of Treatment (EoT)
|
|
Number of patients with adverse events (AEs)
Tidsramme: During treatment, an average of 8 months
|
Frequency, duration, and severity of AEs across treatment groups |
During treatment, an average of 8 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluation of Disease Control Rate (DCR)
Tidsramme: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST 1.1 |
Up to 24 weeks post End of Treatment (EoT)
|
|
Evaluation of Duration of Response (DOR)
Tidsramme: Up to 24 weeks post End of Treatment (EoT)
|
The proportion of patients with DOR |
Up to 24 weeks post End of Treatment (EoT)
|
|
Evaluation of Time to Response (TTR)
Tidsramme: Every 12 weeks during treatment
|
The number of patients with days to response |
Every 12 weeks during treatment
|
|
Evaluation of Progression Free Survival (PFS)
Tidsramme: Up to 24 weeks post End of Treatment (EoT)
|
Patients with number of days of progression free response |
Up to 24 weeks post End of Treatment (EoT)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Mridula George, MD, Rutgers University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Hudsykdommer
- Bryst sykdommer
- Hud- og bindevevssykdommer
- Brystneoplasmer
- Trippel negative brystneoplasmer
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Nukleinsyrer, nukleotider og nukleosider
- Deoxycytidine
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Nukleosider
- Uracil
- Pyrimidinoner
- Deoxyribonucleosides
- Fluorouracil
- Capecitabin
- eniluracil
Andre studie-ID-numre
- PCS6422-BC-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .